Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 15, 1997

View Archived Issues

Synthetic retinoids with anticoagulant effects

SDZ-MRL-953 prevents sepsis in cancer patients

Preclinical profile of Ono-1101 published

SciClone issued European patent for use of thymosin alpha 1 for hepatitis C

Matrix discontinues U.S. development of AccuSite

Biomira reports phase II results for cancer vaccine

Preclinical studies show broad antiseizure properties of ganaxolone

Oncologic Drugs Advisory Committee meets this week

LG Chemical licenses thrombin inhibitor to Warner-Lambert

NC-1800 now in phase II development

Chugai accelerates R&D outside Japan

Pharmacological characterization of BIBU-52

Kirin's TPO enters phase II in several Asian countries

Kyowa Hakko antiparkinsonian enters phase II trials

Amphetamines may provide long-term benefit in patients with ADHD

MIT licenses drug discovery technology to Dyax

Benefits of magnesium sulfate investigated in patients with unstable angina

Cytel and Searle to collaborate on cancer therapies

Myocardial and cerebral vasodilating effects of BMS-180448 in animals

Molecumetics and Teijin begin oral thrombin inhibitor collaboration

Potent GH secretagogues synthesized at Merck & Co.

Gene Logic and Japan Tobacco enter genomic alliance

Novel antibacterial agents from R.W. Johnson

Novartis evaluates SDZ-267-489 and analogues for increasing HDL cholesterol

Cardiovascular effects of SB-209509 and sumatriptan compared in dogs

Hormone therapy vs. simvastatin for hypercholesterolemia in postmenopausal women

Novel neuroprotective agent developed at Takeda

Mitsubishi describes synthesis and activity of MKC-242

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...